BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2017;2:525-34. [PMID: 28355434 DOI: 10.1001/jamacardio.2017.0065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR. Stroke Prevention in Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology 2018;71:2790-801. [DOI: 10.1016/j.jacc.2018.04.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
2 Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski AS, Sanders GD. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. Ann Intern Med 2018;169:774-87. [PMID: 30383133 DOI: 10.7326/M18-1523] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ferro EG, Liu CL, Kazi DS. Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. Heart 2021:heartjnl-2021-319055. [PMID: 33858957 DOI: 10.1136/heartjnl-2021-319055] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Derseh MT, Solomon K, Tamene W, Beneberu W, Yayehrad AT, Ambaye AS. A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia. Clinicoecon Outcomes Res 2021;13:821-34. [PMID: 34557006 DOI: 10.2147/CEOR.S327868] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mark DB, Cowper PA, Anstrom KJ, Sheng S, Daniels MR, Knight JD, Baloch KN, Davidson-Ray L, Fiuzat M, Januzzi JL Jr, Whellan DJ, Piña IL, Ezekowitz JA, Adams KF, Cooper LS, O'Connor CM, Felker GM. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. J Am Coll Cardiol 2018;72:2551-62. [PMID: 30466512 DOI: 10.1016/j.jacc.2018.08.2184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
6 Messori A, Trippoli S. The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit. Heart 2017;103:1746-1746. [DOI: 10.1136/heartjnl-2017-311816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
7 Piayda K, Hellhammer K, Nielsen-Kudsk JE, Schmidt B, Mazzone P, Berti S, Fischer S, Lund J, Montorfano M, Della Bella P, Gage R, Zeus T. Clinical outcomes of patients undergoing percutaneous left atrial appendage occlusion in general anaesthesia or conscious sedation: data from the prospective global Amplatzer Amulet Occluder Observational Study. BMJ Open 2021;11:e040455. [PMID: 33762228 DOI: 10.1136/bmjopen-2020-040455] [Reference Citation Analysis]
8 Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res 2017;121:695-710. [PMID: 28860319 DOI: 10.1161/CIRCRESAHA.117.311849] [Cited by in Crossref: 90] [Cited by in F6Publishing: 40] [Article Influence: 18.0] [Reference Citation Analysis]
9 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]
10 Reddy ST, Cossey T, Savitz SI, Grotta JC. Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal. Curr Neurol Neurosci Rep 2017;17. [DOI: 10.1007/s11910-017-0774-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]